Lead Product(s) : Debio-1453
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $20.2 million
Deal Type : Funding
CARB-X Grants Debiopharm $12.3 Million To Advance Novel Antibiotic for Gonorrhea
Details : The grant will support the continued clinical development of Debio 1453, a first-in-class antibiotic with a novel mechanism of action to treat Neisseria gonorrhoeae infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 28, 2025
Lead Product(s) : Debio-1453
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $20.2 million
Deal Type : Funding
Reset All
